Australia's most trusted
source of pharma news
Posted 21 January 2025 AM
Melbourne-based Neurizon Therapeutics has been hit with a setback from the FDA, which placed its Investigational New Drug (IND) application on hold on Friday.
The IND application, filed last month, is for NUZ-001, Neurizon's flagship product, and is needed for the drug to enter Phase 2 trials to treat Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neuron Disease, as part of the HEALEY ALS Platform Trial. Neurizon had planned to start the trial in the first half of 2025.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.